Latisse: Why Latisse?
Identity Audit
Latisse: Why Latisse? is listed on DirJournal under Beauty Products in United States.
Editorial Verification
200 OK StatusVerified
Primary website is live, secure (HTTPS), and free of malware.
Domain AgeVerified
Real-world domain age (≥1 yr, verified via the Wayback Machine) OR pre-migration legacy ID OR ≥2 years of platform tenure. Survival across multiple search-engine update cycles is itself a trust signal.
Schema ValidationVerified
Valid Organization / ProfessionalService JSON-LD emitted on every page load — checked at render time.
Citation ClarityPending Manual Review
Verified outbound links to at least two authoritative sources (social profiles, sameAs URLs).
Operational HistoryVerified
Minimum 12-month active history in the claimed industry — derived from the business's founding year, Wayback-verified domain age, or listing tenure (any one signal passes).
Entity RegistrationPending Manual Review
Cross-referenced with official state or country business registries.
Physical FootprintData Incomplete
Verified non-virtual presence via Google Maps or official lease documentation.
Complete in DashboardActive LeadershipData Incomplete
Confirmation of key team members and executive roles.
Complete in DashboardNAP ConsistencyData Incomplete
Verified match of Name, Address, and Phone data across platforms.
Complete in DashboardProfessional LicensingPending Manual Review
Verification of required industry-specific certifications or licenses.
Sentiment AuditPending Manual Review
Manual review of third-party reputation signals (BBB, Trustpilot, etc.).
Editorial DiscretionPending Manual Review
Final human review to ensure the business provides genuine value.
This entity has not yet undergone the 12-Point Manual Editorial Audit. The 5 Verified points above are objective system checks this listing already passes; the remaining 7 are manual editorial reviews that still need a human auditor's sign-off.
About
Latisse: Why Latisse details the first and only FDA-approved prescription treatment for inadequate eyelashes, bimatoprost ophthalmic solution 0.03%.
DirJournal's Perspective
This listing focuses on Latisse, the FDA-approved prescription treatment for eyelash enhancement using bimatoprost ophthalmic solution 0.03%. Potential clients should note this listing has been active for one year but remains unverified and has no customer reviews to assess service quality.
Reviewed by DirJournal Editorial Board
Frequently Asked
Latisse: Why Latisse? operates as a regional entity serving United States. This listing is maintained without a single physical address because its service footprint spans the region.
Knows About